Shots:

• The company reported the results of an expanded access trial for Zofin in patients with COVID-19 which was conducted in Houston- TX
• The trial met EPs for safety & efficacy i.e.- improved pulmonary opacities in chest X-rays which showed 83% of patients had normal lung imaging- indicated complete recovery @30 days treatment- improved biomarker levels vs respective control with p-values- mitigated mild and moderate symptoms- was well tolerated with no AEs
• The company will submit this data to FDA for a requested amendment to their approved IND to perform a PBO-controlled P-II clinical trial and also plans to submit results for scientific peer review & publication

  | Ref: Business Wire | Image: BioInformant